

DAFTAR PUSTAKA

- Ahmed, M.I., Aban, I., Lloyd, S.G., Gupta, H., Howard, G., Inusah, S., Peri, K., Robinson, J., Smith, P., McGiffin, D.C., Schiros, C.G., Denney, T., Dell'Italia, L.J., 2012, A Randomized Controlled Phase IIb Trial of Beta1-Receptor Blockade for Chronic Degenerative Mitral Regurgitation, *J Am Coll Cardiol*, **60**(9), 833-838.
- Albright, S.C., Winston, W.L., & Zappe, C.J., 2009, *Data Analysis and Decision Making: With Microsoft Excel 3rd Edition*, 389-392, South-Western Cengage Learning, USA.
- Amin, A., Houmsse, A., Ishola, A., Tyler, J., Houmsse, M., 2016, The Current Approach of Atrial Fibrillation Management, *Avicenna J Med*, **6**(1), 8-16.
- Andayani, T.M., 2013, *Farmakoekonomi Prinsip dan Metodologi dalam Kemila*, M., Evaluasi Penggunaan Proton Pump Inhibitor Secara *Off-label* Pada Pasien Rawat Inap di Rumah Sakit JIH (Jogja International Hospital) Yogyakarta Periode Februari-April 2016, *Tesis*, Universitas Gadjah Mada, Yogyakarta.
- Anonim, 1992, Undang-Undang Kesehatan Nomor 23 tahun 1992 tentang Kesehatan, Departemen Kesehatan RI, Jakarta.
- Anonim, 2011, *Modul Penggunaan Obat Rasional*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Babbie, E., 2008, *The Basic of Social Research*, Sixth Edition, 207-210, Chapman University, California.
- Bailliard, F. & Anderson, R.H., 2009, Review Tetralogy of Fallot, *Orphanet Journal of Rare Disease*, **4**(2).
- Bari, K. & Garcia-Tsao, G., 2012, Treatment of Portal Hypertension, *World J Gastroenterol*, **18**(11), 1166-1175.
- Barlas, S., 2009, New FDA Guidance on Off-label Promotion Falls Short for Everyone, *P&T*, **34**(3), 122-123.
- Bazan, I.S. & Fares, W.H., 2015, Pulmonary hypertension: diagnostic and therapeutic challenges, *Ther Clin Risk Manag*, **11**, 1221-1233.
- Benditt, D.G., Sakaguchi, S., Lurie, K.G., Lu, F., 2007, Sinus Node Dysfunction, *Cardiovasc Med*, **9**, 1925-1941.

- Bernard, B., Lebrech, D., Mathurin, P., Opolon, P., Poynard, T., 1997, Beta-Adrenergic Antagonists in The Prevention of Gastrointestinal Rebleeding in Patients with Cirrhosis: A Meta-Analysis, *Hepatology*, **25**(1), 63-70.
- Biondi, B., Fazid, S., Carella, C., Sabatini, D., Amato, G., Cittadini, A., Bellastella, Lombardi, G., Sacca, L., 1993, Control of Adrenergic Overactivity by Beta Blockade Improves the Quality of Life in Patients Receiving Long Term Suppressive Therapy with Levothyroxine, *J Clin Endocrinol Metab*, **78**, 1028-1033.
- Blasius, H., 2008, Die arzneimittel- und sozialrechtliche Stellung des Off-Label-Use, Unlicensed- Use und Compassionate-Use in Frankreich dalam Vanessa, P., The Impact of Off-Label, Compassionate, and Unlicensed Use on Health Care Laws in Preselected Countries, *Disertasi*, Bonn University, Germany.
- BPOM, 2014, *Informatorium Obat Nasional Indonesia*, Badan Pengawas Obat dan Makanan Republik Indonesia, Jakarta.
- Bradford, D.W., Turner, J.L., & Williams, J.W., 2014, *Off-label Use of Pharmaceuticals: Trends and Drivers*, University of Georgia, Georgia.
- Brezinka, V. & Padmos, I., 1994, Coronary Heart Disease Risk Factors in Women, *Eur Heart J*, **15**, 1571-1584.
- Bugan, B. & Roach, E.C., 2014, Pulmonary Hypertension and Beta Blockers: Where do we stand? Where are we going?, *European Review for Medical and Pharmacological Sciences*, **18**, 229-234.
- Bystritsky, A., Khalsa, S.S., Cameron, M.E., Schiffman, J., Current Diagnosis and Treatment of Anxiety Disorders, *P&T*, **38**(1), 30-38.
- Cassar, A., Holmes, D.R., Rihal, C.S., Gersh, B.J., 2009, Chronic Coronary Artery Disease: Diagnosis and Management, *Mayo Clin Proc*, **84**(12), 1130-1146.
- Chandrashekhkar, Y., Westaby, S., & Narula, J., 2009, Mitral stenosis, *Lancet*, **373**, 1271-1283.
- Clozel, J.P., Danchin, N., Genton, P., Thomas, J.L., Cherrier, F., 1984, Effects of Propranolol and of Verapamil on Heart Rate and Blood Pressure in Hyperthyroidism, *Clin Pharmacol Ther*, **36**(1), 64-69.
- Crosby, N.J., Deane, K., & Clarke, C.E., 2003, Beta-blocker Therapy for Tremor in Parkinson's Disease (Review), *The Cochrane Database Syst Rev*, (1), CD003361.

- DiPiro, J., Talbert, R.L., Yee, G., Wells, B., dan Posey, L.M., 2014, *Pharmacotherapy A Pathophysiologic Approach*, 9th ed, McGraw Hill Professional.
- FDA, *Food And Drug Administration Approved Drug Products*, <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>, 16 April 2017.
- Geva, T., Martins, J.D., & Wald, R.M., 2014, Atrial Septal Defect, *Lancet*, **383**, 1921-1932.
- Garson, A.Jr., Gillete, P.C., & Mcnamara, D.G., 1981, Propranolol: The Preferred Palliation for Tetralogy of Fallot, *Am J Cardiol*, **47**, 1098-1104.
- Geffner, D.L. & Hershman, J.M., 1992, Beta Adrenergic Blockade for The Treatment of Hyperthyroidism, *Am J Med*, **93**, 61-68.
- Gluud, L.L., Klingenberg, S., Nikolova, D., Gluud, C., 2007, Banding Ligation Versus Beta-Blockers as Primary Prophylaxis in Esophageal Varices: Systematic Review of Randomized Trials, *Am J Gastroenterol*, **102**(12), 2842-2848.
- Gregor, P. & Curila, K., 2015, Medical Treatment of Hypertrophic Cardiomyopathy-What Do We Know About it Today?, *Cor et Vasa*, **57**, 219-224.
- Grimard, B.H. & Larson, J.M., 2008, Aortic Stenosis: Diagnosis and Treatment, *Am Fam Physician*, **78**(6), 717-725.
- Groszmann, R.J., Garsia-Tsao, G., Bosch, J., Grace, N.D., Burroughs, A.K., Planas, R., Escorsell, A., Garcia-Pagan, J.C., Patch, D., Matloff, D.S., Gao, H., Makuch, R., 2005, Beta blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis, *N Engl J Med*, **353**, 2254-2261.
- Helfand, M., Peterson, K., Christensen, V., Dana, T., Thakurta, S., 2009, *Drug Class Review: Beta Adrenergic Blockers*, Oregon Health & Science University, Oregon.
- Henderson, J.M., Yiannikas, C., Morris, J.G.L., Einstein, R., Jackson, D., Byth, K., 1994, Postural Tremor of Parkinson's Disease, *Clin Neuro*, **17**, 277-285.
- Higgins, L.C., 1988, Off-Label Rx. Insurers Starting to Balk, *Med World News*, 24 Oktober 1988.

- Hoffman, J.I.E., 2017, Review Article: At What Age Should Tetralogy of Fallot be Corrected, *Cardiology in The Young*, Cambridge University Press.
- Jefferson, D., Wharrad, H.J., Birmingham, A.T., Patrick, J.M., 1987, The Comparative Effects of ICI 118551 and Propranolol on Essential Tremor, *Br J Clin Pharmacol*, **24**(6), 729-734.
- Ji, T., Feng, C., Sun, L., Ye, X., Bal, Y., Chen. Q., Qin, Y., Zhu, J., Zhao, X., 2016, Are Beta Blockers Effective for Preventing Post Coronary Artery Bypass Grafting Atrial Fibrillation? Direct and Network Meta Analyses, *Ir J Med Sci*, **185**(2), 503-511.
- Joenes, Z.N., 1994, *Ars Prescribendi Resep yang Rasional, Jilid 1*, Airlangga Press, Surabaya.
- Katrtsis, D.G., Panagiotakos, D.B., Karvouni, E., Giazitzoglou, E., Korovesis, S., Paxinos, G., Anagnostopoulos, C.E., Camm, A.J., 2003, Comparison of Effectiveness of Carvedilol Versus Bisoprolol for Maintenance of Sinus Rhythm After Cardioversion of Persistent Atrial Fibrillation, *AM J Cardiol*, **92**, 1116-1119.
- King, S.B. & Franch, R.H., 1971, Production of Increased Right-to-left Shunting by Rapid Heart Rates in Patients with Tetralogy of Fallot, *Circulation*, **44**(265).
- Kraus, M.L., Gottlieb, L.D., Horwitz, R.I., Anscher, M., 1985, Randomized Clinical Cotrolled Trial of Atenolol in Patients With Alcohol Withdrawal, *N Engl J Med*, **313**(15).
- Kuntjojo, 2009, *Metodologi Penelitian*, 29-33, Universitas Nusantara PGRI Kediri, Kediri.
- Lin, H.W., Phan, K., & Lin, S.J., 2006, Trends in Off-label Beta-blocker Use: A Secondary Data Analysis, *Clin Ther*, **28**(10), 1710-1711.
- Lin, Z.P., Dong, M., & Liu. J., 2013, Bisoprolol Improved Endothelial Function and Myocardium Survival of Hypertension with Stable Angina: A Randomized Double-Blinded Trial, *Eur Rev Med Pharmacol Sci*, **17**(6), 794-801.
- Lowes, B.D., Gill, E.A., Abraham, W.T., Larrain, J., Robertson, A.D., Bristow, M.R., Gilbert, E.M., 1999, Effects of Carvedilol on Left Ventricular Mass, Chamber Geometry, and Mitral Regurgitation in Chronic Heart Failure, *Am J Cardiol*, **83** (8), 1201-1205.

- Maganti, K., Rigolin, V.H., Sarano, M.E., Bonow, R.O., 2010, Valvular Heart Disease: Diagnosis and Management, *Mayo Clin Proc*, **85**(5), 483-500.
- Mahmoud, A.S., Tantawy, A.E., Kouatli, A.A., Baslaim, G.M., 2007, Propranolol: A New Indication for an Old Drug in Preventing Postoperative Junctional Ectopic Tachycardia After Surgical Repair of Tetralogy of Fallot, *Interact Cardiovasc Thorac Surg*, **7**(2008), 184-187.
- Manickavasagam, S., Merla, R., Koerner, M.M., Kunapuli, S., Rosanio, S., Barbagelata, A., 2009, Management of Hypertension in Chronic Heart Failure, *Expert Rev Cardiovasc Ther*, **7**(4), 423-433.
- Marsden, C.D., Parkes, J.D., & Rees, J.E., 1974, Propranolol in Parkinson's Disease, *Lancet*, **2**(7877), 410.
- Mayer, D., 2010, *Essential Evidence-Based Medicine*, Second Edition, 56-66, Cambridge University Press, Cambridge.
- Mayer, T., & Specht, U., 1995, Propranolol in Startle Induced Epileptic Seizures, *J Neurol Neurosurg Psychiatry*, **58**(3), 382-383.
- Mello, M., Studdert, D.M., & Brennan, T. A., 2009, Shifting Terrain in The Regulation of Off-label Promotion of Pharmaceuticals, *N Engl J Med*, **360**(15), 1557-1566.
- Merkel, C., Marin, R., Angeli, P., Zanella, P., Felder, M., Bernardello, E., Cavallarin, G., Bolognesi, M., Donada, C., Bellini, B., Torbolli, P., Gatta, A., 2004, A Placebo Controlled Clinical Trial of Nadolol in the Prophylaxis of Growth of Small Esophageal Varices in Cirrhosis, *Gastroenterology*, **127**(2), 476-84.
- Metra, M., Nodari, S., Bordonali, T., Milani, P., Lombardi, C., Bugatti, S., Fontanella, B., Verzura, G., Danesi, R., Cas, L. D., 2007, Bisoprolol in the Treatment of Chronic Heart Failure: From Pathophysiology to Clinical Pharmacology and Trial Results, *Ther Clin Risk Manag*, **3**(4), 569-578.
- Mozaffarian, D., Benjamin E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., Das, S.R., De, F.S., Despres, J.P., Fullerton, H.J., Howard, V.J., Huffman, M.D., Isasi, C.R., Jimenez, M.C., Judd, S.E., Kissela, B.M., Lichtman, J.H., Lisabeth, L.D., Liu, S., Mackey, R.H., Maqid, D.J., McGuire, D.K., Mohler, E.R., Moy, C.S., Muntner, P., Mussolino, M.E., Nasir, K., Neumar, R.W., Nichol, G., Palaniappan, L., Pandey, D.K., Reeves, M.J., Rodriguez, C.J., Rosamond, W., Sorlie, P.D., Stein, J., Towfighi, A., Turan, T.N., Virani, S.S., Woo, D., Yeh, R. W., Turner,

- M.B., 2016, Heart Disease and Stroke-Statistic- 2016 Update: A Report from American Heart Association, *Circulation*, **133**(4), 38-360.
- Negreva, M.N. & Penev, A.P., 2012, Effect of Selective Beta-blockade with Bisoprolol in the Treatment of Recent-onset Atrial Fibrillation, *Folia Med (Plovdiv)*, **54**(2), 27-31.
- Nightingale, S.L., 2003, Off-label Use of Prescription Drugs, *Am Fam Physician*, **68** (3), 425-427.
- Nishimura, R.A., Otto, C.M., Bonow, R.O., Carabello, B.A., Erwin, J.P., Guyton, R.A., O’Gara, P.T., Ruiz, C.E., Skubas, N.J., 2014, American Heart Association/American College of Cardiology Guideline for the Management of Patients with Valvular Heart Disease, *J Am Coll Cardiol*, **63** (22), 57-185
- Nistri, S., Olivotto, L., Maron, M.S., Ferrantini, C., Coppini, R., Grifoni, C., Baldini, K., Sgalambro, A., Cecchi, F., Maron, B.J., 2012, Beta Blockers for Prevention of Exercise Induced Left Ventricular Outflow Tract Obstruction in Patients With Hypertrophic Cardiomyopathy, *Am J Cardiol*, **110**, 715-719
- Nuebert, A., Dormann, H., Weiss, J., Criegee-Rieck, M., Rascher, W., Brune, K., Hinz, B., 2004, The Impact of Unlicensed and Off-label Drug Use on Adverse Drug Reactions in Paediatric Patients, *Drug Saf*, **27**(13), 1059-1067.
- Nugroho, A.E., 2013, *Farmakologi Obat Obat Penting dalam Pembelajaran Ilmu Farmasi dan Dunia Kesehatan*, 11-46, Pustaka Pelajar, Yogyakarta.
- Oh, P.C., Kang, W.C., Moon, J., Park, Y.M., Kim, S., Kim, M.G., Lee, K., Ahn, T., Shin, E.K., 2016, Anti-anginal and Metabolic Effects of Carvedilol and Atenolol in Patients with Stable Angina Pectoris: A Prospective, Randomized, Parallel, Open Label Study, *Am J Cardiovasc Drugs*, **16**(3), 221-228.
- Oliveira, G.G.D. & Borges, M.A., 1994, Propranolol Action in Chronically Unstable Generalized Epilepsy, *Am J Ther*, **1**, 38-41.
- Oski, F.A., Miller, L.D., Delivoria-Papadopoulos, M., Manchester, J.H., Shelburne, J.C., Oxygen Affinity in Red Cells: Changes Induced in Vivo by Propranolol, *Science*, **1**, 1372.
- Osuagwu, L.L., Korhonen, M.J., Saano, S., Helin, T.M., Naaranlahti, T., Kokki, H., 2009, Off-label and Unlicensed Drug Prescribing in Three Paediatric

Wards in Finland and Review of the International Literature, *J Clin Pharm Ther*, **34**(3), 277-87.

Peskind, E.R., Tsuang, D.W., Bonner, L.T., Pascualy, M., Rieske, R.G., Snowden, M. B., Thomas, R., Raskind, M. A., 2005, Propranolol for Disruptive Behaviours in Nursing Home Residents with Probable or Possible Alzheimer Disease- A Placebo-Controlled Study, *Alzheimer Dis Assoc Disord*, **19**(1), 23-28.

Plate, V., 2008, Vergleichende Untersuchung des Off-Label-Use, Unlicensed-Use und Compassionate-Use in ausgewählten Industriestaaten: Endbericht zum Forschungsprojekt dalam Vanessa, P., The Impact of Off-Label, Compassionate, and Unlicensed Use on Health Care Laws in Preselected Countries, *Disertasi*, Bonn University, Germany.

Ponce, F.E., Williams, L.C, Webb, H.M., Riopel, D.A., Hohn, A.R., 1973, Propranolol Palliation of Tetralogy of Fallot: Experience with Long-term Drug Treatment in Pediatric Patients, *Pediatric*, **52**(1), 110-116.

Radley, D.C., Finkelstein, S.N., & Stafford, R.S., 2006, Off-label Prescribing Among Office-based Physicians, *Arch Intern Ailed*, **166**(9), 1021-1026.

Rossi, A., Temporelli, P.L., Ciccoira, M., Gaibazzi, N., Cioffi, G., Nistri, S., Magatelli, M., Tavazzi, L., Faggiano, P., 2015, Beta-blockers Can Improve Survival in Medically-treated Patients with Severe Symptomatic Aortic Stenosis, *Int J Cardiol*, **190**, 15-17.

Ryan, Thomas. P, 2013, *Sample Size Determination and Power*, John Wiley & Sons, Inc., Hoboken, New Jersey.

Sackett, D.L., Straus, S.E., & Richardson, W.S., 2000, *Evidence Based Medicine : How to Practice and Teach EBM* dalam Kemila, M., Evaluasi Penggunaan Proton Pump Inhibitor Secara *Off-label* Pada Pasien Rawat Inap di Rumah Sakit JIH (Jogja International Hospital) Yogyakarta Periode Februari-April 2016, *Tesis*, Universitas Gadjah Mada, Yogyakarta.

Sammir, S.S., Mathew, H., Denise, M.G., Pamela, F., Vidya, S., Crayton, F.Jr., Daniel, H., Kathy, J., Marjorie, L.W., Fiona, H.L., James, E.L., David, B., Anthony, D.S., 2007, Off-label Drug Use in Hospitalized Children, *Arch Pediatr Adolesc Med*, **161**(3), 282-290.

Sampat, U., Varadarajan, P., Turk, R., Kamath, A., Khandhar, S., Pai, R.G., 2009, Effect of Beta-blocker Therapy on Survival in Patients with Severe Aortic Regurgitation, *J Am Coll Cardiol*, **54** (5), 452-457.

- Schenker, H.I. & Silver, L.H., 2000, Long-term Intraocular Pressure Lowering Efficacy and Safety of Timolol Maleate Gel-Forming Solution 0,5% Compared with Timoptic XE 0,5% in a 12-Month Study, *Am J Ophthalmol*, **130**(2), 145-150.
- Sivanandan, S. & Agarwal, R., 2016, Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration, *Pediatr Drugs*, **18**(2), 123-138.
- So, P.P., Davies, R.A., Chandy, G., Stewart, D., Beanlands, R.S.B., Haddad, H., Pugliese, C., Mielniczuk, L. M., 2012, Usefulness of Beta-Blocker Therapy and Outcomes in Patients with Pulmonary Arterial Hypertension, *Am J Cardiol*, **109**, 1504-1509.
- Spoladore, R., Maron, M.S., D'amato, R., Camici, P.G., Olivotto, L., 2012, Pharmacological Treatment Options for Hypertrophic Cardiomyopathy: High Time for Evidence, *Eur Heart J*, **33**, 1724-1733.
- Stafford, R.S., 2008. Regulating Off-label Drug Use-Rethinking the Role of the FDA, *New Engl J Med*, **358**, 1427-1429.
- Strang, R.R., 1965, Clinical Trial With A Beta Receptor Antagonist (Propranolol) in Parkinsonism, *J Neurol Neurosurg Psychiatr*, **28**, 404-406.
- Sugimoto, T., Hayakawa, H., Osada, H., Yamazaki, N., Mori, H., Yasuda, H., Sakamoto, A., 1986, Clinical Evaluation of Bisoprolol in the Treatment of Extrasystoles and Sinus Tachycardia: An Interim Report, *J Cardiovasc Pharmacol*, **11**, 171-174.
- Svetlana, I. & Momir., 2015, Reasons for and Frequency of Off-Label Drug Use. *Med Pregl*, **68**, 35-40.
- Tabarrok, A.T., 2000, Assessing the FDA Via The Anomaly of Off-label Drug Prescribing, *The Independent review*, **1**.
- Tagami, T., Yambe, Y., Tanaka, T., Ogo, A., Yoshizumi, H., Kaise, K., Higashi, K., Tanabe, M., Shimazu, S., Usui, T., Shimatsu, A., Naruse, M., BBGD Study Group 2012 Short Term Effects of Beta Adrenergic Antagonists and Methimazole in New-onset Thyrotoxicosis Caused by Graves' Disease, *Intern Med*, **51**, 2285-2290.
- Vanessa, P., 2009, The Impact of Off-Label, Compassionate, and Unlicensed Use on Health Care Laws in Preselected Countries, *Disertasi*, Bonn University, Germany.

- Varadarajan, P., Joshi, N., Appel, D., Duvvuri, L., Pai, R.G., 2008, Effect of Beta Blocker Therapy on Survival in Patients with Severe Mitral Regurgitation and Normal Left Ventricular Ejection Fraction, *Am J Cardiol*, **102**, 611-615.
- Wilton, L.V., Pearce, G., & Mann, R.D., 1999, The Use of Newly Marketed Drugs in Children and Adolescents Prescribed in General Practice, *Pharmacoepidemiol Drug Saf*, **S1**, S37-S45.
- Wittich, C.M., Burkle, C.M., & Lanier, W.L., 2012, Ten Common Questions (and Their Answers) About Off-label Drug Use, *Mayo Clin Proc*, **87**(10), 982-990.
- World Health Organization, 1985, *The Rational Use of Drug*, Report of The Conference of Experts, Nairobi.